Abnova (Taiwan)TPE:4133 +0.48%75 Days Payable is 29.23 as of Dec. 2025, which is 27% above its 10-year median of 23.03. GuruFocus rates TPE:4133 with a GF Score™ of 75/100 and a GF Value™ of NT$28.28 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 702 Biotechnology companies, Abnova (Taiwan) ranks worse than 81.05% on this metric.
The historical rank and industry rank for Abnova (Taiwan)'s Days Payable or its related term are showing as below:
TPE:4133'
s Days Payable Range Over the Past 10 Years
Min: 20.42 Med: 23.03 Max: 32.24
Current: 29.69
During the past 13 years, Abnova (Taiwan)'s highest Days Payable was 32.24. The lowest was 20.42. And the median was 23.03.
TPE:4133's Days Payable is ranked worse than 81.05% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs TPE:4133: 29.69
Abnova (Taiwan)'s Days Payable
declined
from Dec. 2024 (37.54) to Dec. 2025 (29.23).
It may suggest that Abnova (Taiwan)accelerated paying its suppliers.
Abnova (Taiwan) Days Payable Related Terms
Abnova (Taiwan) Days Payable Historical Data
* Premium members only.
The historical data trend for Abnova (Taiwan)'s Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4133 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Abnova (Taiwan)'s Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abnova (Taiwan) Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s Days Payable distribution charts can be found below:
* The bar in red indicates where Abnova (Taiwan)'s Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Abnova (Taiwan)'s Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abnova (Taiwan) (TPE:4133) has a Days Payable of 29.23 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abnova (Taiwan) and its competitors. This is 27% above median its historical median of 23.03. Over the past decade, Abnova (Taiwan)'s Days Payable has ranged from 20.42 to 32.24. According to the industry distribution chart, Abnova (Taiwan) ranks #569 out of 702 companies in the Biotechnology industry, placing it in the top 81.1%.
Is Abnova (Taiwan)'s Days Payable too high?
Abnova (Taiwan)'s current Days Payable of 29.23 is 27% above median its 10-year median of 23.03. Over the past 10 years, this metric has ranged from a low of 20.42 to a high of 32.24. The Biotechnology industry median Days Payable is 113.56. Abnova (Taiwan)'s value of 29.23 is 74.3% below this industry median. Based on the distribution chart, Abnova (Taiwan) ranks #569 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abnova (Taiwan) has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abnova (Taiwan) ranks #569 out of 702 companies for Days Payable. This places Abnova (Taiwan) in the lower half of its industry. The industry median Days Payable is 113.56. Abnova (Taiwan)'s value of 29.23 is 74.3% below this benchmark. Historically, Abnova (Taiwan)'s own Days Payable has ranged from 20.42 to 32.24 over the past decade. While the company's 10-year median is 23.03 vs. the industry median of 113.56, Abnova (Taiwan) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abnova (Taiwan)'s current Days Payable of 29.23 is 74.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abnova (Taiwan) and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abnova (Taiwan)'s current Days Payable is 29.23, which is 27% above median its own 10-year median of 23.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.28, compared to a current price of NT$20.85 — trading 26.3% below its estimated fair value. The current Days Payable is 29.23, which is 27% above median its 10-year median of 23.03 and 74.3% below the Biotechnology industry median of 113.56. Abnova (Taiwan)'s overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current Days Payable is 29.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?
Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued.
The current stock price of NT$20.85 is trading 26.3% below its estimated GF Value™ of NT$28.28.
GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.
Key valuation signals for TPE:4133:
Days Payable: 29.23 (27% above median its 10-year median of 23.03)
GF Value™: NT$28.28 vs. price of NT$20.85 (26.3% below fair value)
Industry Position: 74.3% below the Biotechnology median (#569 of 702)
No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score
Get the complete analysis for TPE:4133
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4133 has been successfully added to your 
